Capital Advisors Inc. OK Sells 52,013 Shares of Pfizer Inc. $PFE

Key Points

• Capital Advisors Inc. OK reduced its Pfizer stake by 2.9%, selling 52,013 shares during the second quarter and retaining 1.77 million shares valued at approximately $42.6 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer exceeded quarterly expectations with earnings of $0.77 per share and revenue of $15.03 billion, while issuing a $0.43 quarterly dividend that yields about 6.2%. However, its dividend payout ratio remains elevated at 226.32%.
• Analysts maintain a consensus “Hold” rating with an average price target of $28.28. Pfizer’s updated COVID-19 vaccine approval and progress on its Lyme disease vaccine support its pipeline, though the narrower COVID-19 market and concerns about dividend sustainability remain risks.

Capital Advisors Inc. OK lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 2.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,770,761 shares of the biopharmaceutical company's stock after selling 52,013 shares during the quarter. Capital Advisors Inc. OK's holdings in Pfizer were worth $42,640,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. lifted its holdings in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer in the fourth quarter worth $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $26,000. HFM Investment Advisors LLC boosted its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 427 shares during the period. Finally, Field & Main Bank bought a new position in Pfizer in the 2nd quarter worth $27,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.2%

PFE opened at $27.95 on Friday. The stock has a 50-day moving average of $25.55 and a 200 day moving average of $26.30. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The firm has a market cap of $159.31 billion, a P/E ratio of 36.78 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio is presently 226.32%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PFE shares. Weiss Ratings cut Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research report on Monday, August 17th. Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. Royal Bank Of Canada raised shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. Finally, Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $28.28.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source